Dare Bioscience (DARE) Operating Margin (2016 - 2026)
Dare Bioscience's (DARE) quarterly Operating Margin came in at 1582.53% in Q2 2026, down 1966207.0% on a YoY basis from N/an in Q2 2025, and down 1001.09% quarter-over-quarter from 143.72% in Q4 2025.
Powered by 
Analysis
Dare Bioscience (DARE) Operating Margin (2016 - 2026) Analysis & Trends
Dare Bioscience (DARE) has reported Operating Margin for 7 consecutive years, with 1582.53% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Operating Margin fell 1966207.0% year-over-year to 1582.53%; the trailing twelve-month figure through Jun 2026 stood at 1001.35% (down 10539355.0% YoY), and the FY2025 full-year result was 1315.51%, up 23837669.0% from the prior year.
- Operating Margin fell to 1582.53% in Q2 2026 per DARE's latest filing, from 143.72% in the prior quarter.
- Across five years, Operating Margin topped out at 18079.54% in Q2 2025 and bottomed at 162340.76% in Q3 2025.
- Historically, Operating Margin has averaged 22119.33% across 5 years, with a median of 1211.09% in 2023.
- The widest YoY moves for Operating Margin: up 5087866 bps in 2025, down 15111208 bps in 2025.
- Over 5 years, Operating Margin stood at 3.84% in 2022, then plunged by 7543 bps to 286.05% in 2023, then soared by 3060 bps to 8465.75% in 2024, then plunged by 102 bps to 143.72% in 2025, then slumped by 1001 bps to 1582.53% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 1582.53%, 143.72%, and 162340.76% for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.64 Bn | 192.65 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.82 Bn | 176.65 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 131.16 Bn | 123.31 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.67 Bn | 73.67 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.28 Bn | 55.09 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 53.91 Bn | 48.77 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.12 Bn | 29.81 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.05 Bn | 29.05 Bn | 1.16 Mn | -25,380.93% |
| 10 | Dare Bioscience | 10.65 Mn | -1.96 Mn | -132,343.00 | -1,582.53% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,582.53% |
| Dec 31, 2025 | -143.72% |
| Sep 30, 2025 | -162,340.76% |
| Jun 30, 2025 | 18,079.54% |
| Mar 31, 2025 | -18,016.75% |
| Dec 31, 2024 | 8,465.75% |
| Sep 30, 2024 | -11,228.68% |
| Jun 30, 2024 | -32,799.12% |
| Mar 31, 2024 | -64,743.85% |
| Dec 31, 2023 | -286.05% |
| Sep 30, 2023 | -839.64% |
| Jun 30, 2022 | 3.84% |
| Jun 30, 2017 | -74.71% |
| Mar 31, 2017 | -19.17% |
| Dec 31, 2016 | -24.63% |